ArticleCancer biology & therapy2020

Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and

Ricardo E Perez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.